Johnson & Johnson (NYSE:JNJ) Shares Sold by SAM Advisors LLC

SAM Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 3.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,433 shares of the company’s stock after selling 708 shares during the period. Johnson & Johnson makes up about 1.6% of SAM Advisors LLC’s investment portfolio, making the stock its 13th biggest holding. SAM Advisors LLC’s holdings in Johnson & Johnson were worth $3,104,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the stock. Magnolia Capital Management Ltd. boosted its position in Johnson & Johnson by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $1,978,000 after acquiring an additional 55 shares during the last quarter. Howard Financial Services LTD. boosted its holdings in shares of Johnson & Johnson by 2.1% in the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after buying an additional 57 shares during the last quarter. American Financial Advisors LLC boosted its holdings in shares of Johnson & Johnson by 2.1% in the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock valued at $481,000 after buying an additional 57 shares during the last quarter. Taylor & Morgan Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock valued at $635,000 after buying an additional 57 shares during the last quarter. Finally, Kwmg LLC boosted its holdings in shares of Johnson & Johnson by 2.6% in the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock valued at $417,000 after buying an additional 59 shares during the last quarter. 68.59% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 1.0 %

JNJ stock opened at $163.28 on Thursday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The stock has a market capitalization of $429.29 billion, a price-to-earnings ratio of 23.77, a PEG ratio of 2.97 and a beta of 0.61. The business’s fifty day moving average price is $168.25 and its two-hundred day moving average price is $174.16. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm had revenue of $24.02 billion for the quarter, compared to analysts’ expectations of $23.85 billion. During the same quarter last year, the business earned $2.48 EPS. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.7 earnings per share for the current year.

Johnson & Johnson declared that its Board of Directors has approved a share buyback program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 1.2% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its shares are undervalued.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.77%. The ex-dividend date was Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. UBS Group cut their price objective on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. SVB Leerink cut their price objective on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Morgan Stanley cut their price objective on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a report on Monday, September 12th. Wells Fargo & Company raised their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Finally, Citigroup cut their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $189.78.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.